Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Eddingpharm licenses Asian rights to Syndax's cancer candidate entinostat

Executive Summary

Chinese drug company Eddingpharm International Holdings Ltd. has licensed exclusive rights in some Asian countries (China, Hong Kong, Thailand, Macau, Taiwan, Malaysia, and Singapore) to develop, manufacture, and sell oncology biotech Syndax Pharmaceuticals Inc.'s late-stage cancer candidate entinostat.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies